Data shown here confirm that MET expression and activation are not sufficient to make MET overexpressing cells, such as ovarian cancer cells, susceptible to METi or to the combined treatment, in line with the report that no synergistic effects of the combined treatment with PARPi and METi were found in cell lines with BRCA1 or BRCA2 deficiency [40]. Here, BRCA2 is linked to ovarian carcinoma.